Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study.

IF 5.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Tony M Keaveny, Annette L Adams, Eric S Orwoll, Sundeep Khosla, Ethel S Siris, Michael R McClung, Mary L Bouxsein, Shireen Fatemi, David C Lee, David L Kopperdahl
{"title":"Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study.","authors":"Tony M Keaveny, Annette L Adams, Eric S Orwoll, Sundeep Khosla, Ethel S Siris, Michael R McClung, Mary L Bouxsein, Shireen Fatemi, David C Lee, David L Kopperdahl","doi":"10.1093/jbmr/zjae090","DOIUrl":null,"url":null,"abstract":"<p><p>Randomized trials have not been performed, and may never be, to determine if osteoporosis treatment prevents hip fracture in men. Addressing that evidence gap, we analyzed data from an observational study of new hip fractures in a large integrated healthcare system to compare the reduction in hip fractures associated with standard-of-care osteoporosis treatment in men versus women. Sampling from 271,389 patients aged ≥ 65 who had a hip-containing CT scan during care between 2005 and 2018, we selected all who subsequently had a first hip fracture (cases) after the CT scan (start of observation) and a sex-matched equal number of randomly selected patients. From those, we analyzed all who tested positive for osteoporosis (DXA-equivalent hip BMD T-score ≤ -2.5, measured from the CT scan using VirtuOst). We defined \"treated\" as at least six months of any osteoporosis medication by prescription fill data during follow-up; \"not-treated\" was no prescription fill. Sex-specific odds ratios of hip fracture for treated vs not-treated patients were calculated by logistic regression; adjustments included age, BMD T-score, BMD-treatment interaction, BMD, race/ethnicity, and seven baseline clinical risk factors. At two-year follow-up, 33.9% of the women (750/2,211 patients) and 24.0% of the men (175/728 patients) were treated primarily with alendronate; 51.3% and 66.3%, respectively, were not-treated; and 721 and 269, respectively, had a first hip fracture since the CT scan. Odds ratio of hip fracture for treated vs not-treated was 0.26 (95% confidence interval: 0.21-0.33) for women and 0.21 (0.13-0.34) for men; the ratio of these odds ratios (men:women) was 0.81 (0.47-1.37), indicating no significant sex effect. Various sensitivity and stratified analyses confirmed these trends, including results at five-year follow-up. Given these results and considering the relevant literature, we conclude that osteoporosis treatment prevents hip fracture similarly in both sexes.</p>","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":" ","pages":"1424-1433"},"PeriodicalIF":5.1000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425693/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Mineral Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jbmr/zjae090","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Randomized trials have not been performed, and may never be, to determine if osteoporosis treatment prevents hip fracture in men. Addressing that evidence gap, we analyzed data from an observational study of new hip fractures in a large integrated healthcare system to compare the reduction in hip fractures associated with standard-of-care osteoporosis treatment in men versus women. Sampling from 271,389 patients aged ≥ 65 who had a hip-containing CT scan during care between 2005 and 2018, we selected all who subsequently had a first hip fracture (cases) after the CT scan (start of observation) and a sex-matched equal number of randomly selected patients. From those, we analyzed all who tested positive for osteoporosis (DXA-equivalent hip BMD T-score ≤ -2.5, measured from the CT scan using VirtuOst). We defined "treated" as at least six months of any osteoporosis medication by prescription fill data during follow-up; "not-treated" was no prescription fill. Sex-specific odds ratios of hip fracture for treated vs not-treated patients were calculated by logistic regression; adjustments included age, BMD T-score, BMD-treatment interaction, BMD, race/ethnicity, and seven baseline clinical risk factors. At two-year follow-up, 33.9% of the women (750/2,211 patients) and 24.0% of the men (175/728 patients) were treated primarily with alendronate; 51.3% and 66.3%, respectively, were not-treated; and 721 and 269, respectively, had a first hip fracture since the CT scan. Odds ratio of hip fracture for treated vs not-treated was 0.26 (95% confidence interval: 0.21-0.33) for women and 0.21 (0.13-0.34) for men; the ratio of these odds ratios (men:women) was 0.81 (0.47-1.37), indicating no significant sex effect. Various sensitivity and stratified analyses confirmed these trends, including results at five-year follow-up. Given these results and considering the relevant literature, we conclude that osteoporosis treatment prevents hip fracture similarly in both sexes.

骨质疏松症治疗对两性髋部骨折的预防效果相似:FOCUS 观察性研究。
目前还没有进行过随机试验来确定骨质疏松症治疗是否能预防男性髋部骨折,而且可能永远不会进行。针对这一证据缺口,我们分析了一项大型综合医疗系统中新发髋部骨折的观察性研究数据,以比较男性和女性接受标准护理骨质疏松症治疗后髋部骨折的减少情况。我们从 271389 名年龄≥ 65 岁、在 2005-2018 年期间接受过髋部计算机断层扫描的患者中抽取样本,选取了所有在 CT 扫描(观察开始)后发生首次髋部骨折的患者(病例),以及随机选取的同等数量的性别匹配患者。从中,我们分析了所有骨质疏松症检测呈阳性的患者(使用 VirtuOst 通过 CT 扫描测量的 DXA 等效髋关节骨矿密度 T 评分≤-2.5)。我们将 "接受过治疗 "定义为在随访期间根据处方配药数据至少服用过 6 个月的任何骨质疏松症药物;"未接受过治疗 "是指未配药。我们通过逻辑回归计算了接受治疗与未接受治疗的患者发生髋部骨折的性别特异性几率比;调整因素包括年龄、骨密度 T 值、骨密度与治疗的交互作用、体重指数、种族/人种和七个基线临床风险因素。在两年的随访中,33.9%的女性(750/2211 例患者)和 24.0% 的男性(175/728 例患者)接受了治疗,主要是阿仑膦酸盐;分别有 51.3% 和 66.3% 的患者未接受治疗;分别有 721 和 269 例患者自 CT 扫描后首次发生髋部骨折。女性接受治疗与未接受治疗的髋部骨折几率比为 0.26(95% 置信区间:0.21-0.33),男性为 0.21(0.13-0.34);这些几率比(男性:女性)为 0.81(0.47-1.37),表明没有显著的性别效应。各种敏感性分析和分层分析证实了这些趋势,包括五年随访的结果。鉴于这些结果并考虑到相关文献,我们得出结论:骨质疏松症治疗对两性预防髋部骨折的效果相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Bone and Mineral Research
Journal of Bone and Mineral Research 医学-内分泌学与代谢
CiteScore
11.30
自引率
6.50%
发文量
257
审稿时长
2 months
期刊介绍: The Journal of Bone and Mineral Research (JBMR) publishes highly impactful original manuscripts, reviews, and special articles on basic, translational and clinical investigations relevant to the musculoskeletal system and mineral metabolism. Specifically, the journal is interested in original research on the biology and physiology of skeletal tissues, interdisciplinary research spanning the musculoskeletal and other systems, including but not limited to immunology, hematology, energy metabolism, cancer biology, and neurology, and systems biology topics using large scale “-omics” approaches. The journal welcomes clinical research on the pathophysiology, treatment and prevention of osteoporosis and fractures, as well as sarcopenia, disorders of bone and mineral metabolism, and rare or genetically determined bone diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信